Anne Duffy1,2, Gin S Malhi3,4, Paul Grof2,5. 1. 1 Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada. 2. 2 Mood Disorders Centre of Ottawa, Ottawa, Ontario, Canada. 3. 3 Department of Psychiatry, Royal North Shore Hospital, New South Wales, Australia. 4. 4 Discipline of Psychiatry and Kolling Institute, Sydney Medical School, University of Sydney, New South Wales, Australia. 5. 5 Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Abstract
OBJECTIVE: The purpose of this study is to address the question of whether a universal staging model of severe psychiatric disorders is a viable direction for future research by examining the extant literature. METHOD: A narrative review was conducted of the relevant historical, conceptual, and empirical literature pertaining to the clinical trajectory of bipolar disorder and schizophrenia and issues relevant to staging. RESULTS: There is substantive evidence that classic recurrent bipolar disorder is separable from schizophrenia on the basis of family history, developmental and clinical course, treatment response, and neurobiological findings. However, because of the intrinsic heterogeneity of diagnostic categories that has been amplified by recent changes in psychiatric taxonomy, key distinctions between the groups have become obfuscated. While mapping risk and illness markers to emerging psychopathology is a logical approach and may be of value for some psychiatric disorders and/or their clinical subtypes, robust evidence supporting identifiable stages per se is still lacking. Presently, even rudimentary stages such as prodromes cannot be meaningfully applied across different disorders and no commonalities can be found for the basis of universal staging. CONCLUSIONS: Advances in the prediction of risk, accurate early illness detection, and tailored intervention will require mapping biomarkers and other risk indicators to reliable clinical phases of illness progression. Given the capricious nature of mood and psychotic disorders, this task is likely to yield success only if conducted in narrowly defined subgroups of individuals at high risk for specific illnesses. This approach is diametrically opposite to that being promulgated by proponents of a universal staging model.
OBJECTIVE: The purpose of this study is to address the question of whether a universal staging model of severe psychiatric disorders is a viable direction for future research by examining the extant literature. METHOD: A narrative review was conducted of the relevant historical, conceptual, and empirical literature pertaining to the clinical trajectory of bipolar disorder and schizophrenia and issues relevant to staging. RESULTS: There is substantive evidence that classic recurrent bipolar disorder is separable from schizophrenia on the basis of family history, developmental and clinical course, treatment response, and neurobiological findings. However, because of the intrinsic heterogeneity of diagnostic categories that has been amplified by recent changes in psychiatric taxonomy, key distinctions between the groups have become obfuscated. While mapping risk and illness markers to emerging psychopathology is a logical approach and may be of value for some psychiatric disorders and/or their clinical subtypes, robust evidence supporting identifiable stages per se is still lacking. Presently, even rudimentary stages such as prodromes cannot be meaningfully applied across different disorders and no commonalities can be found for the basis of universal staging. CONCLUSIONS: Advances in the prediction of risk, accurate early illness detection, and tailored intervention will require mapping biomarkers and other risk indicators to reliable clinical phases of illness progression. Given the capricious nature of mood and psychotic disorders, this task is likely to yield success only if conducted in narrowly defined subgroups of individuals at high risk for specific illnesses. This approach is diametrically opposite to that being promulgated by proponents of a universal staging model.
Authors: Michael Berk; Karen Hallam; Gin S Malhi; Lisa Henry; Melissa Hasty; Craig Macneil; Murat Yucel; Chris Pantelis; Brendan Murphy; Eduard Vieta; Seetal Dodd; Patrick D McGorry Journal: J Ment Health Date: 2010-04
Authors: M Wals; M H Hillegers; C G Reichart; J Ormel; W A Nolen; F C Verhulst Journal: J Am Acad Child Adolesc Psychiatry Date: 2001-09 Impact factor: 8.829
Authors: Mary Cannon; Avshalom Caspi; Terrie E Moffitt; HonaLee Harrington; Alan Taylor; Robin M Murray; Richie Poulton Journal: Arch Gen Psychiatry Date: 2002-05
Authors: Christopher Baethge; Leonardo Tondo; Irene M Bratti; Tom Bschor; Michael Bauer; Adele C Viguera; Ross J Baldessarini Journal: Can J Psychiatry Date: 2003-08 Impact factor: 4.356
Authors: Esther Mesman; Willem A Nolen; Catrien G Reichart; Marjolein Wals; Manon H J Hillegers Journal: Am J Psychiatry Date: 2013-05 Impact factor: 18.112
Authors: Anne Duffy; Tomas Hajek; Martin Alda; Paul Grof; Robert Milin; Glenda MacQueen Journal: Eur Arch Psychiatry Clin Neurosci Date: 2009-04-23 Impact factor: 5.270
Authors: Tomas Hajek; Cynthia Calkin; Ryan Blagdon; Claire Slaney; Rudolf Uher; Martin Alda Journal: Neuropsychopharmacology Date: 2014-06-19 Impact factor: 7.853
Authors: Michael Berk; Robert Post; Aswin Ratheesh; Emma Gliddon; Ajeet Singh; Eduard Vieta; Andre F Carvalho; Melanie M Ashton; Lesley Berk; Susan M Cotton; Patrick D McGorry; Brisa S Fernandes; Lakshmi N Yatham; Seetal Dodd Journal: World Psychiatry Date: 2017-10 Impact factor: 49.548
Authors: Caroline L Vandeleur; Marie-Pierre F Strippoli; Enrique Castelao; Mehdi Gholam-Rezaee; François Ferrero; Pierre Marquet; Jean-Michel Aubry; Martin Preisig Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2017-04-10 Impact factor: 4.328
Authors: Paolo Fusar-Poli; Christoph U Correll; Celso Arango; Michael Berk; Vikram Patel; John P A Ioannidis Journal: World Psychiatry Date: 2021-06 Impact factor: 79.683
Authors: Ralph Kupka; Anne Duffy; Jan Scott; Jorge Almeida; Vicent Balanzá-Martínez; Boris Birmaher; David J Bond; Elisa Brietzke; Ines Chendo; Benicio N Frey; Iria Grande; Danella Hafeman; Tomas Hajek; Manon Hillegers; Marcia Kauer-Sant'Anna; Rodrigo B Mansur; Afra van der Markt; Robert Post; Mauricio Tohen; Hailey Tremain; Gustavo Vazquez; Eduard Vieta; Lakshmi N Yatham; Michael Berk; Martin Alda; Flávio Kapczinski Journal: Bipolar Disord Date: 2021-07-23 Impact factor: 5.345